Compass Therapeutics details cash runway and pipeline progress

Compass Therapeutics ( (CMPX) ) has issued an update.

On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and marketable securities balance of about $209 million as of December 31, 2025, which it expects will fund operations into 2028, and provided a broad corporate update highlighting pipeline momentum and leadership expansion. The company said key progression-free and overall survival analyses in its Phase 2/3 COMPANION-002 trial of tovecimig in biliary tract cancer remain on track for late first quarter 2026, with additional Phase 2 monotherapy data in metastatic colorectal cancer to be showcased at the 2026 ASCO GI Cancers Symposium, where tovecimig has shown differentiated activity versus other anti-VEGF agents. Compass also detailed encouraging early clinical signals from CTX-8371, including durable responses in triple negative breast cancer and a confirmed third response in Hodgkin lymphoma, prompting cohort expansions in triple negative breast cancer and non-small cell lung cancer and exploration of potential accelerated pathways in Hodgkin lymphoma. The company plans to initiate a Phase 1 study of CTX-10726, a PD-1 x VEGF-A bispecific, in the first quarter of 2026 following promising preclinical comparisons, and to start a Phase 2 trial of CTX-471 in NCAM-expressing tumors in the first half of 2026. In parallel, Compass strengthened its senior team with the appointments of Arjun Prasad as chief commercial officer and Cynthia Sirard as chief medical officer, moves aimed at bolstering its commercial and clinical development capabilities as it advances multiple first-in-class bispecific antibodies toward potentially pivotal milestones.

The most recent analyst rating on (CMPX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Compass Therapeutics stock, see the CMPX Stock Forecast page.

Spark’s Take on CMPX Stock

According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.

The score is held back primarily by weak financial performance (minimal revenue, ongoing losses, and persistent cash burn), despite a relatively strong, low-debt balance sheet. Technicals are moderately supportive with an improving longer-term trend and neutral momentum, while valuation is neutral due to a negative P/E and no dividend yield.

To see Spark’s full report on CMPX stock, click here.

More about Compass Therapeutics

Compass Therapeutics, Inc., founded in 2014 and headquartered in Boston, is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics targeting the interplay of angiogenesis, the immune system and tumor growth. Its pipeline of novel bispecific and other antibody candidates is designed to modulate tumor microvasculature, activate anti-tumor immune responses, and relieve immunosuppressive mechanisms, with programs intended for use both as standalone treatments and in combination regimens across multiple difficult-to-treat cancers.

Average Trading Volume: 1,910,185

Technical Sentiment Signal: Buy

Current Market Cap: $887.5M

See more data about CMPX stock on TipRanks’ Stock Analysis page.